Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
Phase 1 Completed
23 enrolled
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
96 enrolled
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Phase 1 Completed
7 enrolled
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
Phase 1 Completed
6 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
139 enrolled
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
20139157 T-VEC
Phase 1 Completed
26 enrolled
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Phase 1 Completed
10 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Phase 1 Completed
10 enrolled
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Phase 1 Completed
27 enrolled
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
19 enrolled
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
97 enrolled